Table 4.
Details for drugs that induced DILD
| Category | Target | n | Category | Target | n | ||
|---|---|---|---|---|---|---|---|
| M (n = 52) | TKI | AKT | 1 | C (n = 58) | Tubulin inhibitor | Taxane | 6 |
| mTOR | 8 | Kinase | 1 | ||||
| Her1 (EGFR) | 2 | Others | 2 | ||||
| VEGF | 4 | Topoisomerase inhibitor | I | 9 | |||
| mAb | CTLA4 | 2 | II | 5 | |||
| IGF‐1R | 4 | Antimetabolite agents | Cytidine | 13 | |||
| Immunotoxin | 2 | Pyrimidine fluoride | 5 | ||||
| CDK inhibitor | 6 | Platinum | 8 | ||||
| Angiopoietin inhibitor | 2 | Antitumor antibiotics | 5 | ||||
| Proteasome inhibitor | 1 | Nitrosourea | 1 | ||||
| Farnesyltransferase inhibitor | 7 | PKC inhibitor | 2 | ||||
| PARP inhibitor | 4 | DNA minor groove binding agent | 1 | ||||
| HDAC inhibitor | 9 | Radiation therapy | 6 | ||||
AKT, serine/threonine‐specific protein kinase; C, cytotoxic agent; CDK, cyclin dependent kinase; CTLA, cytotoxic T‐lymphocyte‐associated protein; EGFR, epidermal growth factor receptor; HDAC, histone deacetylase; IGF‐1R, insulin like growth factor‐1 receptor; M, molecular targeted agent; mAb, monoclonal antibody; mTOR, mammalian target of rapamycin; PARP, poly ADP ribose polymerase; PKC, phosphokinase C; TKI, tyrosine kinase inhibitoror; VEGF, vascular endothelial growth fact.